From Mundane Medicines to Euphorigenic Drugs: How Pharmaceutical Pleasures Are Initiated, Foregrounded, and Made Durable

Overview

Journal Int J Drug Policy

Publisher Elsevier

Specialties Psychiatry
Public Health

Date 2017 Oct 8

PMID 28985994

Authors

Henry Bundy

Gilbert Quintero

Affiliations

Soon will be listed here.

Abstract

Background: Examining how pharmaceuticals are used to induce pleasure presents a unique opportunity for analyzing not only how pleasure is assembled and experienced through distinct consumption practices but also how mundane medicines can become euphorigenic substances.

Methods: Drawing on qualitative research on the non-medical use of prescription drugs by young adults in the United States, this paper utilizes Actor-Network Theory (ANT) to examine how prescription medicines come to produce pleasure.

Results: Our research found an indeterminacy of experience as individuals were initiated into prescription drug pleasures. We also found that euphorigenic effects coalesce and are foregrounded through subsequent use, and that pleasure and other forms of gratification are made durable through repeated and deliberate pharmaceutical consumption.

Conclusion: Understanding how individuals are socialized into pharmaceutical pleasure, and how assemblages act to constitute the euphorigenic potential of pharmaceutical misuse, may allow for more context-appropriate intervention efforts. We suggest that the euphorigenic properties ascribed to prescription drugs are not inherent in their pharmaceutical formulations, but instead emerge through interactions within networks of heterogeneous actants.

References

Agrawal A, Grant J, Waldron M, Duncan A, Scherrer J, Lynskey M . Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: findings in a Midwestern female twin cohort. Prev Med. 2006; 43(2):125-8. DOI: 10.1016/j.ypmed.2006.03.022. View

Nichter M . Coming to our senses: appreciating the sensorial in medical anthropology. Transcult Psychiatry. 2008; 45(2):163-97. DOI: 10.1177/1363461508089764. View

Berridge K, Kringelbach M . Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl). 2008; 199(3):457-80. PMC: 3004012. DOI: 10.1007/s00213-008-1099-6. View

Duff C . The pleasure in context. Int J Drug Policy. 2007; 19(5):384-92. DOI: 10.1016/j.drugpo.2007.07.003. View

Fudala P, Johnson R . Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend. 2006; 83 Suppl 1:S40-7. DOI: 10.1016/j.drugalcdep.2006.01.016. View

Passik S . Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009; 84(7):593-601. PMC: 2704131. DOI: 10.1016/S0025-6196(11)60748-9. View

Moncrieff J, Cohen D . Rethinking models of psychotropic drug action. Psychother Psychosom. 2005; 74(3):145-53. DOI: 10.1159/000083999. View

Dumit J . Drugs for life. Mol Interv. 2004; 2(3):124-7. DOI: 10.1124/mi.2.3.124. View

Yamaguchi K, Kandel D . Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health. 1984; 74(7):673-81. PMC: 1651671. DOI: 10.2105/ajph.74.7.673. View

10.

Moore D . Erasing pleasure from public discourse on illicit drugs: on the creation and reproduction of an absence. Int J Drug Policy. 2007; 19(5):353-8. DOI: 10.1016/j.drugpo.2007.07.004. View

11.

Webster L, Bath B, Medve R . Opioid formulations in development designed to curtail abuse: who is the target?. Expert Opin Investig Drugs. 2009; 18(3):255-63. DOI: 10.1517/13543780902751622. View

12.

Duff C . The place and time of drugs. Int J Drug Policy. 2014; 25(3):633-9. DOI: 10.1016/j.drugpo.2013.10.014. View

13.

Green R, Moore D . 'Kiddie drugs' and controlled pleasure: recreational use of dexamphetamine in a social network of young Australians. Int J Drug Policy. 2009; 20(5):402-8. DOI: 10.1016/j.drugpo.2008.12.002. View

14.

Quintero G . Rx for a party: a qualitative analysis of recreational pharmaceutical use in a collegiate setting. J Am Coll Health. 2009; 58(1):64-70. PMC: 3121101. DOI: 10.3200/JACH.58.1.64-72. View

15.

Chen X, Unger J, Palmer P, Weiner M, Johnson C, Wong M . Prior cigarette smoking initiation predicting current alcohol use: evidence for a gateway drug effect among California adolescents from eleven ethnic groups. Addict Behav. 2002; 27(5):799-817. DOI: 10.1016/s0306-4603(01)00211-8. View

16.

Keane H . Pleasure and discipline in the uses of Ritalin. Int J Drug Policy. 2007; 19(5):401-9. DOI: 10.1016/j.drugpo.2007.08.002. View

17.

Haddock C, Weg M, DeBon M, Klesges R, Talcott G, Lando H . Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males. Prev Med. 2001; 32(3):262-7. DOI: 10.1006/pmed.2000.0802. View

18.

Race K . The use of pleasure in harm reduction: perspectives from the history of sexuality. Int J Drug Policy. 2007; 19(5):417-23. DOI: 10.1016/j.drugpo.2007.08.008. View

19.

Quintero G . Controlled release: a cultural analysis of collegiate polydrug use. J Psychoactive Drugs. 2009; 41(1):39-47. PMC: 3121105. DOI: 10.1080/02791072.2009.10400673. View

20.

Gomart E . Methadone: six effects in search of a substance. Soc Stud Sci. 2002; 32(1):93-135. DOI: 10.1177/0306312702032001005. View